PROCEPT BioRobotics PRCT 深 沪
等待开盘 08-19 09:30:00 美东时间
21.32
+0.230
+1.09%
华盛通- 最 高21.88
- 今 开21.10
- 成交量 81.94万股
- 最 低 21.10
- 昨 收 21.09
- 总市值 12.21亿
- 52周最高 42.43
- 市盈率 静 --
- 换手率 1.43%
- 52周最低 16.665
- 委 比 -67.74%
- 总股本 5727.37万
- 历史最高 103.8099
- 量 比 0.74
- 振 幅 3.70%
- 历史最低 15.38
- 每 手 1
- 风险率 6.06%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多财报速睇 | PROCEPT BioRobotics 2026财年Q2营收0.94亿美元，同比增长19.4%；归母净利润亏损0.27亿美元，同比亏损扩大37.2%
华盛资讯8月6日讯，PROCEPT BioRobotics公布2026财年Q2业绩，公司Q2营收0.94亿美元，同比增长19.4%，归母净利润亏损0.27亿美元，同比亏损扩大37.2%。
08-06 09:10
美股大行评级 | AMD、Arista Networks、Booking 、加特纳、Pinterest、科力斯、Wayfair等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Precigen"买入"评级，目标价从14美元升至18美元；HC Wainwright & Co.：维持Sophia Genetics"买入"评级，目标价从12美元升至14美元
08-06 11:36
PROCEPT gains after Q2 beat; Wells Fargo downgrades
Shares of PROCEPT BioRobotics (PRCT) gained on Wednesday after the surgical robotics company exceeded Street forecasts with its Q2 2026 revenue, even as Wells Fargo downgraded it, citing an abrupt sof...
08-06 01:38
Evercore ISI Group Maintains Outperform on PROCEPT BioRobotics, Lowers Price Target to $23
Evercore ISI Group analyst Vijay Kumar maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Outperform and lowers the price target from $30 to $23.
08-05 22:22
William Blair Downgrades PROCEPT BioRobotics to Market Perform
William Blair analyst Brandon Vazquez downgrades PROCEPT BioRobotics (NASDAQ:PRCT) from Outperform to Market Perform.
08-05 18:55
财报速睇 | PROCEPT BioRobotics 2026财年Q2营收0.94亿美元，同比增长19.3%；归母净利润亏损0.27亿美元，同比亏损扩大37.2%
华盛资讯8月5日讯，PROCEPT BioRobotics公布2026财年Q2业绩，公司Q2营收0.94亿美元，同比增长19.3%，归母净利润亏损0.27亿美元，同比亏损扩大37.2%。
08-05 06:35
医疗机器人公司PROCEPT BioRobotics因折扣披露问题遭证券欺诈诉讼
医疗机器人公司PROCEPT BioRobotics正面临证券欺诈集体诉讼。诉讼指控公司在披露一项未公开的折扣计划方面存在问题，导致其股价大幅下跌。 根...
07-29 03:26
PROCEPT BioRobotics因涉嫌证券欺诈遭集体诉讼，投资者损失惨重
医疗机器人公司PROCEPT BioRobotics Corporation（NASDAQ： PRCT）近日因涉嫌证券欺诈被提起集体诉讼。该公司主要开发用于...
07-27 21:15
PROCEPT BioRobotics因涉嫌证券欺诈遭集体诉讼，投资者损失惨重
医疗机器人公司PROCEPT BioRobotics Corporation（NASDAQ： PRCT）近日因涉嫌证券欺诈被提起集体诉讼。该公司主要开发用于...
07-27 21:15
Mobia Medical Appoints Reza Zadno, Ph.D., to its Board of Directors
Mobia Medical, Inc. has appointed Reza Zadno, Ph.D., as an independent director and member of the Compensation Committee. Dr. Zadno, with over 35 years of medical technology experience, has a track record of leading companies through IPOs and commercial expansion. He currently serves as an Operating Partner at Jolt Capital and a Special Advisor to the American Academy of Ophthalmology. Mobia Medical specializes in stroke recovery solutions, inclu...
07-15 20:05
